The renin-angiotensin system: an old, newly discovered player in immunoregulation

Transplantation Reviews

Volumn 23, Issue 3, 2009, Pages 151-158

  Geara, Abdallah S ^a   Azzi, Jamil ^b   Jurewicz, Mollie ^b   Abdi, Reza ^b  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LACIDIPINE; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RENIN INHIBITOR; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ADAPTIVE IMMUNITY; ANEMIA; ARTICLE; ATHEROSCLEROSIS; CHEMOTAXIS; CHRONIC ALLOGRAFT NEPHROPATHY; DENDRITIC CELL; ERYTHROCYTOSIS; FIBRIN FORMATION; GENETIC POLYMORPHISM; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PARACRINE SIGNALING; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 67049097102     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2009.04.002     Document Type: Article

References (98)

1. Basso N., and Terragnoaa N. History about the discovery of the renin-angiotensin system. Hypertension 38 (2001) 1246-1249
2. Dzau V.J. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertension 12 suppl 4 (1994) 3-10
3. Mulrow P.J. The intrarenal renin-angiotensin system. Curr Opin Nephrol Hypertension 2 (1993) 41-44
4. Van Kats J.P., Schalekamp M.A., Verdouw P.D., Duncker D.J., and Danser A.H. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 60 (2001) 2311-2317
5. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 49 (1996) 578-597
6. Rodríguez-Iturbe B., Pons H., Herrera-Acosta J., et al. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59 (2001) 1626-1640
7. Ruiz-Ortega M., Bustos C., Hernández-Presa M.A., et al. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161 (1998) 430-439
8. Suzuki Y., Ruiz-Ortega M., Lorenzo O., et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 35 (2003) 881-900
9. Friedland J., Setton C., and Silverstein E. Angiotensin converting enzyme: induction by steroids in rabbit alveolar macrophages in culture. Science 197 (1977) 64-65
10. Jankowski V., Vanholder R., van der Giet M., et al. Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension 46 (2005) 591-597
11. Reilly C.F., Tewksbury D.A., Schechter N.M., et al. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem 257 (1982) 8619-8622
12. Shimada K., and Yazaki Y. Binding sites for angiotensin II in human mononuclear leucocytes. J Biochem 84 (1978) 1013-1015
13. Morrissey J.J., and Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 274 (1998) 580-586
14. Kato S., Luyckx V.A., Ots M., et al. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 56 (1999) 1037-1048
15. Weinstock J.V., and Kassab J. Chemotactic response of splenic mononuclear cells to angiotensin II in murine schistosomiasis. J Immunol 137 (1986) 2020-2024
16. Wolf G., Ziyadeh F.N., Thaiss F., et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 100 (1997) 1047-1058
17. Kintscher U., Wakino S., Kim S., et al. Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension 37 (2001) 587-593
18. Lapteva N., Nieda M., Ando Y., et al. Expression of renin-angiotensin system genes in immature and mature dendritic cells identified using human cDNA microarray. Biochem Biophys Res Commun 285 (2001) 1059-1065
19. Nahmod K.A., Vermeulen M.E., Raiden S., et al. Control of dendritic cell differentiation by angiotensin II. FASEB J 17 (2003) 491-493
20. Jurewicz M., McDermott D.H., Sechler J.M., et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 18 (2007) 1093-1102
21. Costerousse O., Allegrini J., Lopez M., Alhenc-Gelas F., et al. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 290 (1993) 33-40
22. Danilov S.M., Sadovnikova E., Scharenborg N., et al. Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hematol 31 (2003) 1301-1309
23. Gomez R.A., Norling L.L., Wilfong N., et al. Leukocytes synthesize angiotensinogen. Hypertension 21 (1993) 470-475
24. Nataraj C., Oliverio M.I., Mannon R.B., et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 104 (1999) 1693-1701
25. Kunert-Radek J., Stepien H., Komorowski J., et al. Stimulatory effect of angiotensin II on the proliferation of mouse spleen lymphocytes in vitro is mediated via both types of angiotensin II receptors. Biochem Biophys Res Commun 198 (1994) 1034-1039
26. Hoch N.E., Guzik T.J., Chen W., et al. Regulation of T cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 296 (2009) R208-R216
27. Sagawa K., Nagatani K., Komagata Y., et al. Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. Arthritis Rheum 52 (2005) 1920-1928
28. Weidanz J.A., Jacobson L.M., Muehrer R.J., et al. AT1R blockade reduces IFN-γ production in lymphocytes in vivo and in vitro. Kidney Int 67 (2005) 2134-2142
29. Katwa L.C., Campbell S.E., Tyagi S.C., et al. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol 29 (1997) 1375-1386
30. Abbate M., Zoja C., Rottoli D., et al. Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int 61 (2002) 2066-2077
31. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63 (2004) 423-432
32. Johnson R.J., Alpers C.E., Yoshimura A., et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 19 (1992) 464-474
33. Suzuki Y., Lopez-Franco O., Gomez-Garre D., et al. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1. Am J Pathol 159 (2001) 1895-1904
34. Cruzado J.M., Rico J., and Grinyó J.M. The renin angiotensin system blockade in kidney transplantation: pros and cons. Transpl Int 21 (2008) 304-313
35. Ersoy A., Kahvecioglu S., Ersoy C., et al. Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. Transplant Proc 37 (2005) 2148-2150
36. Midtvedt K., Hartmann A., Foss A., et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 72 (2001) 1787-1792
37. Hiremath S., Fergusson D., Doucette S., et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 7 (2007) 2350-2360
38. Formica Jr. R.N., Friedman A.L., Lorber M.I., et al. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 21 (2006) 1389-1394
39. Heinze G., Mitterbauer C., Regele H., et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17 (2006) 889-899
40. Opelz G., Zeier M., Laux G., et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 17 (2006) 3257-3262
41. Vadivel N., Tullius S.G., and Chandraker A. Chronic allograft nephropathy. Semin Nephrol 27 (2007) 414-429
42. Nankivell B.J., Borrows R.J., Fung C.L., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326-2333
43. Border W.A., and Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331 (1994) 1286-1292
44. Castilla A., Prieto J., and Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 324 (1991) 933-940
45. Nakamura T., Miller D.E., Ruoslawri E., et al. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β1. Kidney Int 41 (1992) 1213-1221
46. Kopp J.B., Factor V.M., Mozes M., et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 74 (1996) 991-1003
47. Border W.A., and Noble N.A. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 51 5 (1997) 1388-1396
48. Shihab F.S., Andoh T.F., Tanner A.M., et al. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int 49 (1996) 1141-1151
49. Shihab F.S., Andoh T.F., Tanner A.M., et al. Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy. Am J Kidney Dis 30 (1997) 71-81
50. Ketteler M., Noble N.A., and Border W.A. Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis?. Annu Rev Physiol 57 (1995) 279-295
51. Noble N.A., and Border W.A. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target?. Semin Nephrol 17 (1997) 455-466
52. Border W.A., and Noble N.A. Interactions of TGF-β and angiotensin II in renal fibrosis. Hypertension 31 (1998) 181-188
53. Carvajal G., Rodríguez-Vita J., Rodrigues-Díez R., et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 74 (2008) 585-595
54. Rodríguez-Vita J., Sánchez-López E., Esteban V., et al. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111 (2005) 2509-2517
55. Yamada K., Hatakeyama E., Arita S., et al. Prediction of chronic renal allograft dysfunction from evaluations of TGFBeta1 and the renin-angiotensin system. Clin Exp Nephrol 7 (2003) 238-242
56. Boratyńska M. Urine excretion of transforming growth factor-beta1 in chronic allograft nephropathy. Ann Transplant 4 (1999) 23-28
57. Tylicki L., Biedunkiewicz B., Chamienia A., et al. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 7 (2007) 243-248
58. El-Agroudy A.E., Hassan N.A., Foda M.A., et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 23 (2003) 300-306
59. Campistol J.M., Iñigo P., Jimenez W., et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 56 (1999) 714-719
60. Iñigo P., Campistol J.M., Lario S., et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta (1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 12 (2001) 822-827
61. Hetzel G.R., Hermsen D., Hohlfeld T., et al. Effects of candesartan and perindopril on renal function, TGF-beta1 plasma levels and excretion of prostaglandins in stable renal allograft recipients. Clin Nephrol 57 (2002) 296-302
62. Shihab F.S., Bennett W.M., Tanner A.M., et al. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 52 (1997) 660-673
63. Shang M.H., Yuan W.J., Zhang S.J., et al. Intrarenal activation of renin angiotensin system in the development of cyclosporine A induced chronic nephrotoxicity. Chin Med J (Engl) 121 (2008) 983-988
64. Bonnardeaux A., Davies E., Jeunemaitre X., et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24 (1994) 63-69
65. Jeunemaitre X., Gimenez-Roqueplo A.P., Celerier J., et al. Angiotensinogen variants and human hypertension. Curr Hypertens Rep 1 (1999) 31-41
66. Schmidt S., Strojek K., Grzeszczak W., et al. Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant 12 (1997) 427-429
67. Hueso M., Alia P., Moreso F., et al. Angiotensin converting enzyme genotype and chronic allograft nephropathy in protocol biopsies. J Am Soc Nephrol 15 (2004) 2229-2236
68. Jacobsen P.K., Tarnow L., and Parving H.H. Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?. Kidney Int 69 (2006) 1293-1295
69. Harden P.N., Geddes C., Rowe P.A., et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 345 (1995) 1540-1542
70. Rubattu S., Di Angelantonio E., Stanzione R., et al. Gene polymorphisms of the renin-angiotensin-aldosterone system and the risk of ischemic stroke: a role of the A1166C/AT1 gene variant. J Hypertens 22 (2004) 2129-2134
71. Jin J.J., Nakura J., Wu Z., et al. Association of angiotensin II type 2 receptor gene variant with hypertension. Hypertens Res 26 (2003) 547-552
72. Abdi R., Tran T.B., Zee R., et al. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation 72 (2001) 726-729
73. Ayed K., Ayed-Jendoubi S., Ben Abdallah T., et al. Polymorphism of the renin-angiotensin-aldosterone system in patients with chronic allograft dysfunction. Transpl Immunol 15 (2006) 303-309
74. Bantis C., Ivens K., Kreusser W., et al. Influence of genetic polymorphisms of the renin-angiotensin system on IgA nephropathy. Am J Nephrol 24 (2004) 258-267
75. Jain S., Li Y., Patil S., et al. A single-nucleotide polymorphism in human angiotensinogen gene is associated with essential hypertension and affects glucocorticoid induced promoter activity. J Mol Med 83 (2005) 121-131
76. Fujisawa T., Ikegami H., Kawaguchi Y., et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 41 (1998) 47-53
77. Hunt S.C., Cook N.R., Oberman A., et al. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II. Hypertension 32 (1998) 393-401
78. Reis K., Arinsoy T., Derici U., et al. Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. Clin Transplant 19 (2005) 10-14
79. Rodriguez-Moreno A., Sanchez-Fructuoso A.I., Ridao-Cano N., et al. Association of the genetic polymorphisms of the renin-angiotensin system with kidney graft long-term outcome: preliminary results. Transplant Proc 37 (2005) 3716-3717
80. Savin M., and Petronic V. The significance of angiotensin-converting enzyme inhibitors genotype for ACEi response in patients with chronic allograft nephropathy. Srp Arh Celok Lek 133 (2005) 194-198
81. Smit-van Oosten A., Navis G., Stegeman C.A., et al. Chronic blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation. J Pathol 194 (2001) 122-129
82. Dragun D., Müller D.N., Bräsen J.H., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352 (2005) 558-569
83. Dragun D. Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol Dial Transplant 22 (2007) 1819-1822
84. Dragun D. The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection. Pediatr Nephrol 22 (2007) 911-914
85. Mackenzie H.S., Ziai F., Nagano H., et al. Candesartan cilexetil reduces chronic renal allograft injury in Fisher->Lewis rats. J Hypertens Suppl 15 (1997) 21-25
86. Benediktsson H., Chea R., Davidoff A., et al. Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Effect on structure and function. Transplantation 62 (1996) 1634-1642
87. Amuchastegui S.C., Azzollini N., Mister M., et al. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 9 (1998) 1948-1955
88. Ziai F., Nagano H., Kusaka M., et al. Renal allograft protection with losartan in Fisher->Lewis rats: hemodynamics, macrophages, and cytokines. Kidney Int 57 (2000) 2618-2625
89. Noris M., Azzollini N., Pezzotta A., et al. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J Am Soc Nephrol 12 (2001) 1937-1946
90. Szabo A., Lutz J., Schleimer K., et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 57 (2000) 982-991
91. Lutz J., Risch K., Liu S., et al. Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy. Kidney Int 70 (2006) 1080-1088
92. Lin J., Valeri A.M., Markowitz G.S., et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 73 (2002) 783-788
93. Bravo P., Felgueiras J., Santos C., et al. Angiotensin-converting enzyme inhibitors after renal transplantation. Transplant Proc 40 (2008) 740-742
94. Heinze G., Collins S., Benedict M.A., et al. The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival. Transplantation 82 (2006) 1441-1448
95. Artz M.A., Hilbrands L.B., Borm G., et al. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 19 (2004) 2852-2857
96. Zaltzman J.S., Nash M., Chiu R., et al. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 19 (2004) 940-944
97. Stigant C.E., Cohen J., Vivera M., et al. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 35 (2000) 58-63
98. Montanaro D., Gropuzzo M., Tulissi P., et al. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients. Transplant Proc 37 (2005) 991-993